Report cover image

AI-Based Clinical Trials Solution Provider Market: Segmented: By Clinical Trial Phase (Phase-I, Phase-II, Phase-III), By Therapeutic Application (Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Metabolic Diseases, Infectious Diseas

Publisher Fatpos Global
Published Feb 01, 2023
Length 207 Pages
SKU # FAGL17845491

Description

AI-Based Clinical Trials Solution Provider Market: Segmented: By Clinical Trial Phase (Phase-I, Phase-II, Phase-III), By Therapeutic Application (Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Metabolic Diseases, Infectious Diseases, Others), By End User (Pharmaceutical Companies, Academia, Others), And Region – Global Analysis of Market Size, Share & Trends For 2021–2022 And Forecasts To 2033

Market Overview

The report, AI-Based Clinical Trials Solution Provider Market- Analysis of Market Size, Share & Trends for 2014 - 2022 and Forecasts to 2032, was published by Fatpos Global and is expected to reach Market Value. Fatpos Global conducted a study. The report, in order to provide a thorough understanding of the global market, emphasises the detailed understanding of some key factors, such as size, share, sales, forecast trends, supply, production, demands, industry, and CAGR.

The AI-Based Clinical Trials Solution Provider Market grew from USD 2.56 billion in 2022 to USD 16.0 billion by 3032, exhibiting a CAGR of 18.2% during the forecast period.

Key Companies Profiled
  • Deep Lens Inc.
  • Hematology-Oncology Associates of CNY
  • GlaxoSmithKline plc
  • Genentech
  • AiCure LLC
  • Aiforia
  • Antidote Technologies Inc.
  • Avantor Inc.
  • Deep 6 AI
  • Innoplexus Consulting Services Pvt Ltd
  • Intelligencia.ai
  • MEDIAN Technologies
  • Pharmaceutical Pipeline Enhancement Strategies LLC
  • Saama Technologies Pvt Ltd
  • Simplifai AS
  • Other Prominent Players
AI-Based Clinical Trials Solution Provider Market: Segmentation
  • By Clinical Trial Phase
  • Phase-I
  • Phase-II
  • Phase-III
  • By Therapeutic Application
  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases or Conditions
  • Metabolic Diseases
  • Infectious Diseases
  • Others
  • By End User
  • Pharmaceutical Companies
  • Academia
  • Others
  • AI-Based Clinical Trials Solution Provider Market Dynamics
  • Size Supply and Demand AI-Based Clinical Trials Solution Provider Market
  • Current Issues/Trends/Challenges
  • Companies and Competition Market Drivers and Restraints Involved in the Market Value Chain
  • The report sheds light on various aspects and provides answers to pertinent market questions. Among the most important are:
  • Pre- and post-business impact analysis of COVID-19
  • A thorough examination of the parent market
  • Market dynamics in the industry are changing.
  • Market segmentation in depth
  • What is the AI-Based Clinical Trials Solution Provider Market expansion?
  • Which segment had the highest AI-Based Clinical Trials Solution Provider Market share?
  • Who are the main characters in AI-Based Clinical Trials Solution Provider Market?
  • Historical, current, and projected market volumes and values
  • Trends and developments in the industry recently
  • The competitive environment
  • Key players' strategies and products on offer
  • Potential and niche segments, as well as geographical regions with promising growth prospects
  • A balanced assessment of market performance
  • Information that markets participants must have in order to maintain and expand their market footprint.
Note: Although Fatpos Global has taken great care to ensure the highest levels of accuracy in its studies, it might take some time for significant changes to the market or a particular vendor to be reflected in the research.

*Please Note: The report will be delivered in 4-5 business days upon order confirmation*

Table of Contents

207 Pages
1 Executive Summary
2 Global AI-Based Clinical Trials Solution Provider Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3 Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4 Average Pricing Analysis
5 Macro-Economic Indicators
6 Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7 Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8 Recent Development, Policies & Regulatory Landscape
9 Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10 Global AI-Based Clinical Trials Solution Provider Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11 Global AI-Based Clinical Trials Solution Provider Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12 Global Oncology Pharmaceuticals Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Type: Market Share (2020-2030F)
12.2.1. Chemotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Targeted Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Immunotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Hormonal Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Indication: Market Share (2020-2030F)
12.3.1. Lung Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Stomach Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Breast Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Prostate Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End user: Market Share (2020-2030F)
12.4.1. Specialized cancer treatment centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Hospitals Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Retail Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13 Company Profile
Deep Lens Inc.
Hematology-Oncology Associates of CNY
GlaxoSmithKline plc
Genentech
AiCure LLC
Aiforia
Antidote Technologies Inc.
Avantor Inc.
Deep 6 AI
Innoplexus Consulting Services Pvt Ltd
Intelligencia.ai
MEDIAN Technologies
Pharmaceutical Pipeline Enhancement Strategies LLC
Saama Technologies Pvt Ltd
Simplifai AS
Other Prominent Players
14 Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us